Project description
A novel therapy for glioblastoma
Glioblastoma is the most aggressive brain tumour and is characterised by dismal patient survival. Currently, surgical resection is the gold standard care, which however fails to remove all cancer cells, leading to recurrence. The EU-funded EpiGlioT project is addressing the limited treatments for glioblastoma, focusing on the cases that are resistant to conventional therapeutics. Researchers have developed a strategy for knocking down lysine-specific demethylase 1 (LSD1), an enzyme that is overexpressed in many cancers and targets epigenetic modifications of histones, serving as a gene expression regulator. EpiGlioT is supporting a feasibility study towards the development of LSD1 as a novel glioblastoma therapeutic that will improve patient survival and reduce healthcare costs.
Objective
The goal of this project is to develop a successful treatment that combats the progression of glioblastoma and improve patients’ quality of life. Glioblastoma, the most malignant brain tumour, leads to disproportionately high morbidity in patients and impacts the economy through high mortality rates. The available treatment options are highly ineffective and pose a significant challenge to the healthcare budgets of all nations.
Beactica aims to address this challenge by developing novel compound to inhibit the overexpressed in cancers protein LSD1. Beactica’s programme is based on a verified LSD1 knockdown technique and proves markedly more effective with glioblastoma clones that are resistant to other therapeutics. This way, Beactica’s compounds effectively clear cancer cells from which brain tumour might grow anew and will reduce the risk of relapses.
This therapy will improve intervention outcomes for patients and lower additional treatment and healthcare costs including longer hospitalisation and further medical procedures. This programme is unique and there are no competitors using the same approach to treat glioblastoma by knockdown of the LSD1 protein with a small molecule.
The ultimate success of this project will depend on the generation of clinical data which will improve opportunities for out-licensing. Beactica plans to apply for SME Phase 2 grant to take the lead compound through the clinical Phase I/IIa, and then reach the pharmaceutical market by an agreement with a strong licence partner. Beactica has an established business development contact network and has already gained trust of external investors in this innovative technology.
The problem of cancer is growing dramatically and has been highlighted in the recent policy focus by the European Commission and the World Health Organisation. In this light, Beactica is assured of the significant impact the LSD1 knockdown innovation will have on the glioblastoma burden in Europe and worldwide.
Fields of science (EuroSciVoc)
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
- social sciences sociology demography mortality
- natural sciences biological sciences biochemistry biomolecules proteins
- medical and health sciences clinical medicine oncology
You need to log in or register to use this function
We are sorry... an unexpected error occurred during execution.
You need to be authenticated. Your session might have expired.
Thank you for your feedback. You will soon receive an email to confirm the submission. If you have selected to be notified about the reporting status, you will also be contacted when the reporting status will change.
Programme(s)
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
-
H2020-EU.2.3. - INDUSTRIAL LEADERSHIP - Innovation In SMEs
MAIN PROGRAMME
See all projects funded under this programme -
H2020-EU.3. - PRIORITY 'Societal challenges
See all projects funded under this programme -
H2020-EU.2.1. - INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies
See all projects funded under this programme
Topic(s)
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Funding Scheme
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
SME-1 - SME instrument phase 1
See all projects funded under this funding scheme
Call for proposal
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
(opens in new window) H2020-EIC-SMEInst-2018-2020
See all projects funded under this callCoordinator
Net EU financial contribution. The sum of money that the participant receives, deducted by the EU contribution to its linked third party. It considers the distribution of the EU financial contribution between direct beneficiaries of the project and other types of participants, like third-party participants.
754 50 UPPSALA
Sweden
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.